Direct answer. Tricuspid regurgitation is backward leakage from the right ventricle into the right atrium when the tricuspid valve should be closed. Small imaging findings and clinically important disease have different implications. The cause, severity, right-heart response and other cardiac or pulmonary conditions guide care. Confidence is high in these distinctions; current specialist recommendations are attributed clinical context, not an independently cleared device-efficacy ranking. NHLBI valve anatomy and types, March2022; Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
- Tricuspid leakage affects the right-sided filling valve and differs from pulmonary-valve leakage.
- Primary leaflet disease, chamber-related secondary disease and a device-lead interaction require different assessment.
- Swelling and congestion can reflect right-heart consequences, but their cause cannot be diagnosed at home.
- A pacemaker lead present on a scan does not prove that it caused the leak.
- Diuretics, treatment of associated illness and selected valve intervention have different goals; advanced deterioration should not be ignored while waiting for a larger echo label.
Evidence summary
| Question | Source role | Conclusion and confidence |
|---|---|---|
| Where does blood return? | Public anatomy | From right ventricle to right atrium. High confidence. |
| Does a lead prove causation? | 2025 diagnostic distinction | No. Interaction and an incidental association must be separated. |
| Does a lower leak grade prove every outcome? | Evidence boundary | No. Symptoms, chamber changes, admissions and survival differ. |
| Which treatment applies? | Attributed specialist care | Cause, stage, right-heart/pulmonary findings and anatomy guide individualized assessment. |
Confidence is high in the condition distinctions and need for appropriate assessment. The treatment section attributes clinical guidance; it does not certify the funding of every underlying intervention trial. Independent comparative outcome certainty and a supplement replacement regimen were not established by this focused review. A public institution or independent review cannot make a sponsored original trial financially independent.
What it is
The tricuspid valve separates the right atrium and ventricle. It opens for filling and should close during ventricular contraction. Regurgitation sends blood backward into the atrium. It is different from tricuspid stenosis, which restricts the opening, and from pulmonary regurgitation at the right ventricle’s outlet valve. More than one valve can be affected. NHLBI valve anatomy and types, March2022.
A small leak found on echo is not equivalent to severe symptomatic disease. Important leakage can coexist with right-heart enlargement, impaired function and systemic congestion. Symptoms can include fatigue, reduced capacity, swelling or breathlessness, but these are shared by other cardiac and non-cardiac illnesses. An imaging label and a symptom therefore both need clinical interpretation. NHLBI valve disease symptoms, March2022; Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
Primary regurgitation involves an abnormal valve apparatus, including selected congenital, infectious or other leaflet processes. Secondary leakage relates to altered right-atrial/ventricular size or geometry and inadequate leaflet closure. A pacemaker or defibrillator lead can be involved, but it may also be present without causing the leak. The current guideline distinguishes device-related causation from device-associated coexistence. Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
How it works
When important blood flow returns to the atrium, pressure and congestion can be transmitted to the veins and other organs. The right ventricle may also face volume load, altered pulmonary afterload or an associated muscle problem. Liver and kidney findings can become relevant to assessment and procedural risk. These consequences are not mandatory in every minor leak, and swelling alone does not prove a valve cause. Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
Secondary disease can be associated with atrial enlargement and atrial fibrillation or with ventricular enlargement/dysfunction, pulmonary pressure problems or left-sided disease. These patterns can overlap as disease progresses. Treating the relevant underlying illness matters, but it should not be assumed that correcting a left-sided valve will necessarily eliminate an established severe right-sided leak. Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
Echo assesses the valve’s anatomy, integrated severity, right-sided size/function and pulmonary or venous findings. Selected MRI can quantify right-ventricular volumes/function; CT or transoesophageal echo can help with procedural planning. Catheter assessment may clarify pulmonary haemodynamics in an intervention evaluation. A single estimated pressure, especially in severe regurgitation, does not provide the entire physiological picture. NHLBI valve disease diagnosis, March2022; Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
The evidence-based treatments
Care first clarifies the cause and relevant accompanying disease. Congestion may be managed with clinician-selected diuretics; heart failure, rhythm problems or a defined pulmonary vascular condition may need a separate treatment pathway. Pulmonary-hypertension medicines are not a generic prescription for every leak or every elevated pressure estimate. Medicines and monitoring should have a documented indication. NHLBI valve care background, March2022; Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
The 2025 guideline advises expert assessment of significant disease before advanced right-heart or other organ deterioration makes treatment less suitable. Symptoms, right-ventricular response, pulmonary findings, anatomy, operative risk and likelihood of recovery enter the decision. A temporary reduction in swelling from a diuretic does not by itself settle whether a valve intervention assessment is needed. These are attributed recommendations with explicit funding limitations. Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
Surgical repair or replacement and selected catheter approaches are options in appropriate circumstances. If left-sided surgery is planned, the right-sided valve may also require a considered decision. Catheter methods differ in whether they repair or replace and in anatomical requirements and hazards. This guide does not turn improved leak grading or a symptom composite into a universal survival claim, and does not rank devices using sponsored outcomes. Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
A lead-associated finding needs joint valve/rhythm expertise when a lead may be contributing or may interfere with an intervention. Lead extraction, repositioning or a different pacing strategy has its own risks and is not an automatic response to seeing a lead next to a leaking valve. The clinical team should explain the evidence for interaction, the device’s continuing purpose and the proposed alternatives. Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
Supplement and lifestyle evidence
Activity, nutrition, fluid and salt advice should follow the documented congestion, underlying illness and treatment. Avoiding smoking and reviewing alcohol or drug exposure supports general cardiac health, but does not prove that a stretched valve ring or damaged leaflet has recovered. Changes in swelling or body weight can be useful clinical observations when a team provides an action plan; they are not a home diagnosis. NHLBI valve care background, March2022.
No supplement is established here as a treatment for tricuspid regurgitation. “Heart support,” improved vessel relaxation, a changed blood marker and fewer clinical events are different claims. The cited source set does not provide a fully financially screened trial basis for replacing diagnosis or prescribed care. Correcting a clinician-confirmed deficiency is a separate indication; a retail blend is not a diagnostic test or an emergency treatment.
What works and what does not
Useful care identifies the leak’s cause, current stage, right-heart and pulmonary findings and the goal of each treatment. It distinguishes congestion relief from an anatomical procedure and specifies how benefit and adverse effects will be reviewed. A successful technical intervention does not automatically clear accompanying heart failure, pulmonary vascular disease or a rhythm indication. Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
Ask which outcome is being pursued: symptoms, physiological findings, recurrence, hospital admission or survival. A plan should also say how adverse effects and deterioration will be recognized. Personal stories and before-and-after readings cannot separate treatment effects from the natural course, other medicines or selection of patients. Manufacturer or materially conflicted outcome claims do not determine this article’s independent verdict.
Risks and side effects
Severe breathing difficulty, collapse, new concerning chest pain or sudden major deterioration needs emergency help. Rapidly increasing swelling, new fainting, important palpitations or a substantial drop in capacity deserves prompt assessment according to severity. Do not assume that all swelling is a routine valve fluctuation or independently increase diuretics to suppress an urgent change. NHS current national heart valve disease education.
Diuretics can cause excessive volume loss, low pressure, kidney problems or electrolyte changes. Valve procedures can cause bleeding, stroke, infection, cardiac injury, residual dysfunction and conduction problems requiring pacing. A device-lead procedure adds lead- and pacing-related risks. Anticoagulation and other post-procedure care depend on the chosen intervention and separate clinical indications. NHLBI valve care background, March2022; Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
Important interactions
Review diuretics, rhythm and heart-failure medicines, anticoagulants and supplements with the responsible team. Kidney, liver and electrolyte changes can affect medicine safety. If a pacemaker or defibrillator is present, inform all procedural teams; avoid unplanned medicine or device changes based on a general account of lead-related regurgitation. Any pulmonary vascular prescription needs its own established indication. Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
Bring prescription medicines, non-prescription products, recreational drugs and supplements to the same medication review. Product names alone may hide several active ingredients. The prescriber or pharmacist should check the exact combination and kidney function, rather than treating “natural” as a safety category. Never add a second person’s rescue medicine or stop an important prescribed medicine because an internet list mentions a possible interaction.
Who needs assessment
Ask whether the mechanism is primary, secondary, device-related or mixed; how severity was integrated; and what the right ventricle, pulmonary circulation and other organs show. The team should clarify any uncertain cause of symptoms and whether imaging under different loading conditions or selected haemodynamic testing would change care. Consumer measurements cannot settle procedural suitability. NHLBI valve disease diagnosis, March2022; Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
Pregnancy planning, a previous valve intervention, kidney disease and anticoagulant use deserve specific review. The current status of the valve matters more than an old diagnostic label. Children with congenital disease need an age-appropriate specialist pathway rather than an adult intervention rule. NHLBI valve disease and pregnancy, March2022.
Clinician-led use and follow-up
Ask when symptoms, congestion, kidney/liver findings, right-ventricular function and leak severity will be reviewed and what triggers earlier contact. After a procedure, clarify prosthesis/repair monitoring, rhythm/device checks and antithrombotic instructions. Pregnancy planning and other surgery may require additional review. No personal dose or device-selection threshold is supplied here. NHLBI valve disease and pregnancy, March2022; Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
This guide gives no personal drug, device or supplement dose. The appropriate plan depends on the established diagnosis, current stability, other illnesses and local services. Ask for a written explanation of the treatment purpose, warning signs, review schedule and contact route for side effects. Clinical monitoring and informed consent should accompany any change; study exposures are not prescriptions.
Animal and in-vitro evidence
Laboratory work on valve calcification, connective tissue or blood-flow mechanics can help investigate a mechanism. It cannot determine a safe human supplement dose, establish that a calcified valve will reopen, or select an implant for an individual. An animal or cell finding does not replace a clinical assessment of anatomy, severity and complications. No animal or in-vitro result contributes to this guide’s independent clinical verdict.
Funding and source roles
Who paid for the evidence?
Follow named sources to the funding and relationships disclosed in this article. Numbered article disclosures preserve notes where a source is not identified. A public or university name alone does not establish independence.
View 16 more funding disclosures
This graphic reorganizes the article's disclosures; it is not a new financial audit or independence classification. Highlighted notes show different funding relationships where available. Review funding is separate from underlying trial funding. Disclosure is not proof of falsehood, and no declared conflict is not proof of complete independence.
Financial interests include echocardiography and advanced imaging, valve implants, surgical and catheter services, medicines and marketed supplements. Valve-device manufacturers and professional societies can have relevant financial relationships even when the document itself reports no direct industry-development funding. Those routes and unresolved author/trial chains are shown below; no manufacturer or materially conflicted outcome claim establishes this guide’s independent verdict.
The condition has no corporate owner. Medicines, diagnostics, devices, procedures and marketed supplements create different revenue incentives. This describes financial interests rather than misconduct. Funding tier evaluates proximity to the subject; A–D credibility assesses transparency, accuracy incentives and remaining uncertainty. An unresolved link stays unresolved, and a provisional public-information label does not clear the trials behind it.
| Source | Funding / backers | Country / jurisdiction | Independence | Credibility / incentives / gaps |
|---|---|---|---|---|
| NHLBI valve anatomy and types, March2022 | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | B provisional. Public accountability and educational review favour accuracy; institutional priorities, simplification, dated wording and untraced trial ties remain. Role: Dated public anatomy and distinctions between stenosis, regurgitation and prolapse. |
| NHLBI valve disease causes, March2022 | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | B provisional. Public accountability and educational review favour accuracy; institutional priorities, simplification, dated wording and untraced trial ties remain. Role: Dated public inherited and acquired contributor education. |
| NHLBI valve disease symptoms, March2022 | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | B provisional. Public accountability and educational review favour accuracy; institutional priorities, simplification, dated wording and untraced trial ties remain. Role: Public symptom education; symptoms do not establish severity. |
| NHLBI valve disease diagnosis, March2022 | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | B provisional. Public accountability and educational review favour accuracy; institutional priorities, simplification, dated wording and untraced trial ties remain. Role: Clinical investigation background; no self-diagnostic thresholds. |
| NHLBI valve care background, March2022 | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | B provisional. Public accountability and educational review favour accuracy; institutional priorities, simplification, dated wording and untraced trial ties remain. Role: Dated public procedure/adverse-effect background; oversimplified tissue-valve anticoagulation wording not reproduced. |
| NHS current national heart valve disease education | DHSC funds the national NHS website; its policy states no advertising or corporate sponsorship. Named authors, page-level budget and full underlying trial conflicts unresolved. | United Kingdom; England national public-information service. Other jurisdictions have different services. | Tier 1 public education provisional; not a clearance of original studies. | B provisional. Public-service remit and editorial checks support accuracy; simplification, service priorities and incomplete trial-finance tracing limit inference. Role: January 2025 national condition and emergency education; broad prolapse wording not reproduced. |
| Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF | The original guideline states document development was financed entirely by ESC and EACTS without healthcare-industry involvement. ESC institutional revenues nevertheless include life-science and medtech partnerships; EACTS discloses industry/charity grants and an Edwards Lifesciences Foundation partnership. That separate route does not prove Edwards funded this guideline. The official 2025 author declaration report returned 403 and was not read. Article allocation, individual author independence and original device/drug trial chains remain unresolved. | France: ESC, Sophia Antipolis. United Kingdom: EACTS, Windsor, registered England and Wales; OUP publisher UK. International writing panel. The unchanged original EJCTS PDF mirror is hosted by MATCVS, Malaysia; it does not change the document author or funding origin. Edwards corporate headquarters Irvine, California, US; specific supplied-device manufacturing origin unresolved. | Tier 2 documented society industry routes, with unresolved author chain; independent efficacy excluded. | C provisional. Original 109-page guideline and August 2026 correction checked. Detailed methodology, specialist review and explicit evidence grades aid attributed clinical use; society commercial routes, inaccessible author declarations and uncleared original-trial finances prevent a clean independent outcome verdict. Role: Current 2025 specialist care context with August2026 correction checked; C provisional, not independent efficacy. |
| NHLBI valve disease and pregnancy, March2022 | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | B provisional. Public accountability and educational review favour accuracy; institutional priorities, simplification, dated wording and untraced trial ties remain. Role: Pregnancy planning and medication-safety context. |
| NHLBI valve disease definitions, March2022 | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | B provisional. Public accountability and educational review favour accuracy; institutional priorities, simplification, dated wording and untraced trial ties remain. Role: Additional original linked in condition-specific education or follow-up. |
| NHLBI budget | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 3 institutional financial self-disclosure. | B provisional. Direct public financial policy, with legal accountability; actual gift donors and allocations not audited. Financial provenance only. |
| NHLBI Gift Fund | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 3 institutional financial self-disclosure. | B provisional. Direct public financial policy, with legal accountability; actual gift donors and allocations not audited. Financial provenance only. |
| NHS national website funding policy | DHSC funds the national NHS website; its policy states no advertising or corporate sponsorship. Named authors, page-level budget and full underlying trial conflicts unresolved. | United Kingdom; England national public-information service. Other jurisdictions have different services. | Tier 3 editorial and financial self-disclosure. | B provisional. Explicit funding policy; actual individual declarations and implementation not audited. Financial provenance only. |
| ESC funding and revenue model | ESC directly reports life-science and medtech partnership income alongside memberships, congresses, publishing and education. Its July 2026 policy manages industry remuneration and other interests; reporting a policy is not proof that all bias is removed. | France; ESC European Heart House, Sophia Antipolis; multinational professional society. | Tier 3 institutional self-disclosure; financially interested in its own governance description. | B provisional for stated revenue routes; C where relied on to certify its own clinical independence. Financial transparency supports checking; actual amounts, implementation and document allocations not audited. Financial provenance only. |
| ESC conflict management policy | ESC directly reports life-science and medtech partnership income alongside memberships, congresses, publishing and education. Its July 2026 policy manages industry remuneration and other interests; reporting a policy is not proof that all bias is removed. | France; ESC European Heart House, Sophia Antipolis; multinational professional society. | Tier 3 institutional self-disclosure; financially interested in its own governance description. | B provisional for stated revenue routes; C where relied on to certify its own clinical independence. Financial transparency supports checking; actual amounts, implementation and document allocations not audited. Financial provenance only. |
| EACTS current industry/charity grant and Edwards Foundation relationship | EACTS explicitly offers industry/charity-sponsored outreach grants and names Edwards Lifesciences Foundation for Every Heartbeat Matters; a separate industry-sponsorship contact is provided. Edwards confirms funding, product donations and matching-gift routes. EACTS annual revenue amounts, complete donor list, guideline allocation and individual author finances were not fully traced. This is a documented institutional relationship, not evidence that Edwards directly financed the valve guideline. | United Kingdom; EACTS House, Windsor, registered company and charity in England and Wales. Edwards corporate headquarters Irvine, California, United States; global manufacturing locations differ from grant or guideline jurisdiction. | Tier 3 institutional financial self-disclosure; society has a stake in its own governance description. | B provisional for documented relationships and registered contact; C if used to certify clinical independence. Direct named support improves transparency; amounts, contract terms, full donor and page/author chains remain unresolved. Financial provenance only. |
| EACTS industry sponsorship route | EACTS explicitly offers industry/charity-sponsored outreach grants and names Edwards Lifesciences Foundation for Every Heartbeat Matters; a separate industry-sponsorship contact is provided. Edwards confirms funding, product donations and matching-gift routes. EACTS annual revenue amounts, complete donor list, guideline allocation and individual author finances were not fully traced. This is a documented institutional relationship, not evidence that Edwards directly financed the valve guideline. | United Kingdom; EACTS House, Windsor, registered company and charity in England and Wales. Edwards corporate headquarters Irvine, California, United States; global manufacturing locations differ from grant or guideline jurisdiction. | Tier 3 institutional financial self-disclosure; society has a stake in its own governance description. | B provisional for documented relationships and registered contact; C if used to certify clinical independence. Direct named support improves transparency; amounts, contract terms, full donor and page/author chains remain unresolved. Financial provenance only. |
| EACTS registered jurisdiction and Windsor contact | EACTS explicitly offers industry/charity-sponsored outreach grants and names Edwards Lifesciences Foundation for Every Heartbeat Matters; a separate industry-sponsorship contact is provided. Edwards confirms funding, product donations and matching-gift routes. EACTS annual revenue amounts, complete donor list, guideline allocation and individual author finances were not fully traced. This is a documented institutional relationship, not evidence that Edwards directly financed the valve guideline. | United Kingdom; EACTS House, Windsor, registered company and charity in England and Wales. Edwards corporate headquarters Irvine, California, United States; global manufacturing locations differ from grant or guideline jurisdiction. | Tier 3 institutional financial self-disclosure; society has a stake in its own governance description. | B provisional for documented relationships and registered contact; C if used to certify clinical independence. Direct named support improves transparency; amounts, contract terms, full donor and page/author chains remain unresolved. Financial provenance only. |
| Edwards corporate/foundation funding and technology-donation routes | Edwards Lifesciences corporate/foundation self-disclosure. It describes charitable funding, technology donations, employee matching and annual recipients. Corporate device sales and reputation create a direct interest; no corporate clinical outcome claim is used as independent evidence. Foundation-wide donors, grant contract terms and specific product provenance were not audited. | United States; Edwards Lifesciences corporate global headquarters Irvine, California. The opened location page names US manufacturing and says manufacturing is multinational; a headquarters is not the origin of every implant. | Tier 4 maker-associated corporate/foundation self-disclosure; clinical outcome claims excluded. | D for clinical promotion; provisional B only for explicit self-reported addresses and funding routes cross-checked with EACTS. Commercial and reputational incentives remain. Financial provenance only. |
| Edwards global headquarters and manufacturing-location disclosure | Edwards Lifesciences corporate/foundation self-disclosure. It describes charitable funding, technology donations, employee matching and annual recipients. Corporate device sales and reputation create a direct interest; no corporate clinical outcome claim is used as independent evidence. Foundation-wide donors, grant contract terms and specific product provenance were not audited. | United States; Edwards Lifesciences corporate global headquarters Irvine, California. The opened location page names US manufacturing and says manufacturing is multinational; a headquarters is not the origin of every implant. | Tier 4 maker-associated corporate/foundation self-disclosure; clinical outcome claims excluded. | D for clinical promotion; provisional B only for explicit self-reported addresses and funding routes cross-checked with EACTS. Commercial and reputational incentives remain. Financial provenance only. |
Frequently asked questions
Is every echo leak dangerous? No. Severity, symptoms and right-heart effects determine the meaning of the finding. Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
Does my pacemaker prove the cause? No. A causative interaction must be distinguished from a lead that is simply present. Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
Can diuretics repair the valve? They can treat congestion when indicated. That differs from correcting leaflet, annular or lead-related anatomy. NHLBI valve care background, March2022.
Does treating the left valve settle the right one? Not automatically. Established severe tricuspid disease requires its own assessment and follow-up. Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
Sources and funding notes
- NHLBI valve anatomy and types, March2022 — Dated public anatomy and distinctions between stenosis, regurgitation and prolapse.
- NHLBI valve disease causes, March2022 — Dated public inherited and acquired contributor education.
- NHLBI valve disease symptoms, March2022 — Public symptom education; symptoms do not establish severity.
- NHLBI valve disease diagnosis, March2022 — Clinical investigation background; no self-diagnostic thresholds.
- NHLBI valve care background, March2022 — Dated public procedure/adverse-effect background; oversimplified tissue-valve anticoagulation wording not reproduced.
- NHS current national heart valve disease education — January 2025 national condition and emergency education; broad prolapse wording not reproduced.
- Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF — Current 2025 specialist care context with August2026 correction checked; C provisional, not independent efficacy.
- NHLBI valve disease and pregnancy, March2022 — Pregnancy planning and medication-safety context.
- NHLBI valve disease definitions, March2022 — Additional original linked in condition-specific education or follow-up.
- NHLBI budget — Financial provenance only.
- NHLBI Gift Fund — Financial provenance only.
- NHS national website funding policy — Financial provenance only.
- ESC funding and revenue model — Financial provenance only.
- ESC conflict management policy — Financial provenance only.
- EACTS current industry/charity grant and Edwards Foundation relationship — Financial provenance only.
- EACTS industry sponsorship route — Financial provenance only.
- EACTS registered jurisdiction and Windsor contact — Financial provenance only.
- Edwards corporate/foundation funding and technology-donation routes — Financial provenance only.
- Edwards global headquarters and manufacturing-location disclosure — Financial provenance only.
Original clinical pages and their relevant financial disclosures were opened. The original 109-page 2025 ESC/EACTS valve guideline was read from MATCVS’s unchanged EJCTS/OUP PDF mirror, with its title, authors and DOI verified. The official August 6, 2026 correction was opened separately. The official author-declaration PDF returned 403 and was not read. Actual ESC, EACTS and Edwards financial-route disclosures were checked; separate institutional industry support does not establish direct industry financing of this document. Individual author and original-trial financial chains remain unresolved; clinical recommendations are C-provisional context. Clinical sources concentrate on US and English public education plus European professional guidance. This limits jurisdictional breadth: referral, implant availability and treatment systems vary, and no global access claim is inferred. Guidance, classification, emergency education and independent efficacy are distinct source roles. A full systematic review, complete society donor audit and author-by-author clearance of original treatment trials were not completed.
Last reviewed: October 4, 2026. Educational information, not a diagnosis or personal treatment plan. Use your local emergency service for an emergency.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.